214 related articles for article (PubMed ID: 30718698)
1. Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.
Guo T; Li X; Yang X; Kong X; Liu H; Bai T; Xu K; Ye J; Song Y
Sci Rep; 2019 Feb; 9(1):1231. PubMed ID: 30718698
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.
Kan X; Ye J; Rong X; Lu Z; Li X; Wang Y; Yang L; Xu K; Song Y; Hou X
Sci Rep; 2016 Nov; 6():37998. PubMed ID: 27897243
[TBL] [Abstract][Full Text] [Related]
3. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
[TBL] [Abstract][Full Text] [Related]
5. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
6. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
7. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
Gao H; Li N; Wang JY; Zhang SC; Lin G
J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
[TBL] [Abstract][Full Text] [Related]
8. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
9. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
10. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
Lin G; Wang JY; Li N; Li M; Gao H; Ji Y; Zhang F; Wang H; Zhou Y; Ye Y; Xu HX; Zheng J
J Hepatol; 2011 Apr; 54(4):666-73. PubMed ID: 21146894
[TBL] [Abstract][Full Text] [Related]
11. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features.
Zhou H; Wang YX; Lou HY; Xu XJ; Zhang MM
Korean J Radiol; 2014; 15(2):218-25. PubMed ID: 24643319
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases.
Shin NY; Kim MJ; Lim JS; Park MS; Chung YE; Choi JY; Kim KW; Park YN
Eur Radiol; 2012 Apr; 22(4):864-71. PubMed ID: 22108766
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome.
Wang C; Wu X; Xie W; Ren X; Zhang W; Xu J
Sci Rep; 2019 Feb; 9(1):2179. PubMed ID: 30778132
[TBL] [Abstract][Full Text] [Related]
14. Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI.
Palm V; Sheng R; Mayer P; Weiss KH; Springfeld C; Mehrabi A; Longerich T; Berger AK; Kauczor HU; Weber TF
Cancer Imaging; 2018 Mar; 18(1):9. PubMed ID: 29490696
[TBL] [Abstract][Full Text] [Related]
15. Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors.
Zhang F; Zhou Y; Yang X; Xiong AZ; Wang ZT; Yang L
Acta Pharmacol Sin; 2019 Jun; 40(6):781-789. PubMed ID: 30367152
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase.
Torrisi C; Picone D; Cabibbo G; Matranga D; Midiri M; Brancatelli G
Eur J Radiol; 2018 Oct; 107():39-45. PubMed ID: 30292271
[TBL] [Abstract][Full Text] [Related]
17. Quantitative CT assessment by histogram and volume ratio in pyrrolizidines alkaloids-induced hepatic sinusoidal obstruction syndrome.
Yang X; Lei P; Song Y; Fei Z; Ai Y; Shang H; Bai T; Ye J; Li X
Eur J Radiol; 2021 May; 138():109632. PubMed ID: 33711570
[TBL] [Abstract][Full Text] [Related]
18. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization.
Hwang J; Kim YK; Jeong WK; Choi D; Rhim H; Lee WJ
Radiology; 2015 Jul; 276(1):137-46. PubMed ID: 25734551
[TBL] [Abstract][Full Text] [Related]
19. Gynura segetum induces hepatic sinusoidal obstruction syndrome in a child: A case report.
Zheng Q; Zhang H
Medicine (Baltimore); 2024 Mar; 103(11):e37341. PubMed ID: 38489699
[TBL] [Abstract][Full Text] [Related]
20. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
